论文部分内容阅读
幽门螺杆菌是引起慢性胃炎、消化道溃疡、胃癌及胃相关性淋巴瘤的主要病因之一,1994年被WHO列为1类致癌因子.其在世界范围有约50％的感染率,在2014年的京都共识上建议所有的Hp感染患者均需要根治.但是,随着近年来其耐药率的不断增加,传统三联疗法的根治率正逐渐下将,因此,一直迫切需要寻找到更好的替代或者辅助疗法.而益生菌因其本身较高的安全性以及在提高根治率、减轻不良反应、提高患者应从性等方面表现出的优势,受到很多研究者的关注.本文就近年来益生菌治疗幽门杆菌感染的相关研究进行综述.“,”Helicobacter pylori is a key cause of chronic gastritis,a gastrointestinal ulcer,gastric cancer,and gastric lymphoma.In 1994,the WHO classified H.pylori as a class 1 carcinogen.H.pylori has an infection rate of around 50％ worldwide,and the Kyoto global consensus report of 2014 recommended that all patients with an H.pylori infection be treated.However,the eradication rate of the conventional triple therapy has gradually decreased as the drug resistance of H.pylori had increased in recent years.The urgent need is to find a better alternative or adjuvant therapy.Probiotics can increase the eradication rate since they are highly safe,they cause few adverse reactions,and they can improve patient compliance.Aspects like these are evidence of the advantages of probiotics,and leading many researchers to focus their attention on probiotics.This article summarizes recent research on probiotics to treat H.pylori infection.